Fig. 2

NT1014 inhibited cell proliferation in ovarian cancer cells. The expression of OCT1, OCT2, and OCT3/4 in the IGROV-1 and SKOV3 cell lines was detected by Western blotting (a). The IGROV-1 and SKOV3 cells were incubated with NT1014 (from 0.01 to 3000 μM) in 96-well plates for 72 h, and cell proliferation was assessed by MTT assay (b). MTT assay also used to compare the growth inhibition of metformin and NT1014 in both cells (c, d). NT1014 inhibited cell growth in nine primary cultures of ovarian cancer (e). IGROV-1 and SKOV3 cells were treated with NT1014 in a time course fashion or treated with different doses for 24 h, and expression of OCT1, OCT2 and OCT3/4 was determined by Western blotting. Equal loading was confirmed with an anti-β-actin antibody (f). NT1014 increased the expression of phos-AMPK and decreased phos-S6 expression in both cells after 24 h of treatment (g). *p < 0.05 and **p < 0.01